Are there other solutions for those who refuse the vaccine or who cannot access it?
Since the start of the Sars-CoV-2 pandemic, the pharmaceutical industry in general and major institutions in the northern hemisphere have focused their research on the development of recent vaccines and drugs, such as remdesivir.
There have been groups of researchers who have looked at older, inexpensive, and potentially effective products against Sars-CoV-2.
The most famous of these is hydroxychloroquine. Because it has been the subject of more than 200 studies, 35 of which were randomized, with diametrically opposed conclusions that have raised competing interests, conflicts of interest and doubts.
Nitazoxanide is currently in phase 3, that which precedes possible marketing. It would have prophylactic virtues against Covid-19.
Why shouldn't ivermectin be overlooked?
Ivermectin is almost harmless except for rare contraindications. This product blocks the Sars-CoV-2 protein, but does not kill it, preventing its multiplication (for the record, an infected cell creates between 100 and 1000 RNA viruses).
The prescription is a single 15 mg dose or a 12 mg oral dose for 4 days in a row.
Neurological toxicity has been reported, without death, at a very high dose: 45 g per day.
What is this product?
It is a broad spectrum pest control effective against 129 different insects and 183 worms. It is marketed in more than 90 countries.
In our country it is used against scabies, but it is mainly used against lymphatic filariasis and a scourge in Africa which makes blind people, affecting 40 million people: onchocerciasis.
Ivermectin also has various antiviral properties, particularly for certain RNA viruses such as Sars-CoV-2.
Are there any studies?
In Argentina, 1,195 caregivers, distributed in 4 centers, in contact with Covid-19 patients, were divided into 2 groups: in the first group, 788 caregivers received ivermectin and in the second group, the 407 caregivers had no treatment. After 10 weeks, no caregiver in the first group was infected. In contrast, 237 out of 407 caregivers were infected in the second group without drugs.
Ivermectin has been used in numerous clinical studies: 10 randomized, 7 prophylactic studies, 6 at first symptoms and 15 in late and severe stages.
Its effectiveness appears to be significant and convincing at all stages and in all trials except for 2 trials involving very small numbers of people. In one case, the subjects were too young, which made it impossible to see a difference with the placebo group and in the other case, the doses administered were too low.
According to these studies, including 1500 patients from randomized studies, ivermectin reduces viral load within 2 or 3 days, shortens the clinical course and decreases mortality.
Studies, except one, show that ivermectin is spiked by doxycycline, an antibiotic that has anti-Sars-CoV-2 effects.
India markets a kit combining zinc with ivermectin and doxycycline.
Magnetizer Carbone, December 20, 2020